We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




DNA and Protein Composite Vaccine Produces Long Lasting Immunity Against Chagas Disease in Mice

By LabMedica International staff writers
Posted on 17 May 2015
Print article
Image: Micrograph showing T. cruzi (some marked by arrows) in the heart (Photo courtesy of Dr. Nisha J. Garg, University of Texas Medical Branch).
Image: Micrograph showing T. cruzi (some marked by arrows) in the heart (Photo courtesy of Dr. Nisha J. Garg, University of Texas Medical Branch).
A candidate vaccine for Chagas disease was found to induce long-lasting immunity against the Trypanosoma cruzi parasite in mice.

Chagas disease, or American trypanosomiasis, is a tropical parasitic disease caused by the protozoan Trypanosoma cruzi. It is spread mostly by insects known as Triatominae or kissing bugs. The symptoms change over the course of the infection. In the early stage, symptoms are typically either not present or mild and may include fever, swollen lymph nodes, headaches, or local swelling at the site of the bite. After eight to 12 weeks, individuals enter the chronic phase of disease, and in 60%–70% of cases it never produces further manifestations. The other 30%–40% of people develop further symptoms 10 to 30 years after the initial infection, including enlargement of the ventricles of the heart in 20%–30% of cases, which may lead to heart failure.

Investigators at the University of Texas Medical Branch (Galveston, USA) had previously obtained promising results with a vaccine that contained three particular parasite proteins. In the current study, they expanded on the earlier work by vaccinating mice with a combination of two of the T. cruzi proteins (TcG2 and TcG4), which had proven to be the most potent in provoking both an antibody and a T-cell immune response.

The investigators immunized C57BL/6 mice with the TcG2/TcG4 vaccine delivered by a DNA-prime/Protein-boost (D/P) approach. In this procedure the first injection contained DNA coding for the TcG2 and TcG4 proteins, and the second, three weeks later, contained a mix of the two proteins themselves. Some mice were also given a booster immunization three months later, which consisted of the mix of the two proteins (D/P/P regimen).

Results published in the May 7, 2015, online edition of the journal PLOS Pathogens revealed that mice challenged with T. cruzi immediately after immunization with the D/P vaccine were capable of controlling 90%–97% of the acute parasitemia and tissue parasite burden, and, subsequently, inflammatory infiltrate and tissue fibrosis were particularly absent in the heart and skeletal muscle of vaccinated mice.

D/P vaccination elicited CD4+ (30-38%) and CD8+ (22-42%) T-cells that maintained an effector phenotype up to 180 days following vaccination and were capable of responding to antigenic stimulus or challenge infection by a rapid expansion with type I cytokine production and cytolytic T-lymphocyte activity. Subsequently, challenge infection at 120 or 180 days following vaccination, resulted in two to three-fold lower parasite burden in vaccinated mice than was noted in unvaccinated/infected mice.

Summing up the results, the investigators said, "The TcG2/TcG4 D/P vaccine provided long-term anti-T. cruzi T-cell immunity, and booster immunization would be an effective strategy to maintain or enhance the vaccine-induced protective immunity against T. cruzi infection and Chagas disease. The next steps toward clinical studies in humans will include characterizing the quality and quantity of immunity to the vaccine candidates in naïve individuals."

Related Links:

University of Texas Medical Branch


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
LH ELISA
Luteinizing Hormone ELISA
New
ELISA System
ABSOL HS DUO

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.